Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Collegium Pharmaceutical
COLL
5
Enerpac Tool
EPAC
(Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 11.22%4.69B | 12.22%19.84B | 10.17%4.87B | 11.43%5.44B | 12.81%5.31B | 15.00%4.22B | 10.54%17.68B | 8.60%4.42B | 11.69%4.88B | 12.27%4.7B |
Operating revenue | 11.22%4.69B | 12.22%19.84B | 10.17%4.87B | 11.43%5.44B | 12.81%5.31B | 15.00%4.22B | 10.54%17.68B | 8.60%4.42B | 11.69%4.88B | 12.27%4.7B |
Cost of revenue | 9.27%3.01B | 7.93%12.76B | 7.13%3.16B | 7.50%3.47B | 8.06%3.37B | 9.25%2.76B | 7.20%11.82B | 3.45%2.95B | 9.72%3.22B | 8.84%3.12B |
Gross profit | 14.91%1.68B | 20.89%7.08B | 16.28%1.71B | 19.08%1.97B | 22.16%1.94B | 27.67%1.46B | 17.97%5.86B | 20.65%1.47B | 15.72%1.66B | 19.72%1.58B |
Operating expense | 3.93%858.6M | 20.83%3.58B | 15.25%903.2M | 19.64%949.8M | 28.94%901.3M | 20.30%826.1M | 16.39%2.96B | 22.66%783.7M | 14.51%793.9M | 14.07%699M |
Selling and administrative expenses | 3.93%858.6M | 20.83%3.58B | 15.25%903.2M | 19.64%949.8M | 28.94%901.3M | 20.30%826.1M | 16.39%2.96B | 22.66%783.7M | 14.51%793.9M | 14.07%699M |
-General and administrative expense | ---- | ---- | ---- | ---- | 28.94%901.3M | 20.30%826.1M | ---- | ---- | ---- | --699M |
Operating profit | 29.20%818.9M | 20.94%3.5B | 17.45%807.6M | 18.56%1.02B | 16.81%1.03B | 38.75%633.8M | 19.64%2.89B | 18.43%687.6M | 16.86%864.2M | 24.60%885.4M |
Net non-operating interest income expense | -0.74%-54.8M | 7.58%-202.5M | 8.85%-48.4M | 12.15%-47.7M | 10.94%-52.1M | -2.26%-54.4M | -2.24%-219.1M | -2.31%-53.1M | -1.69%-54.3M | -7.54%-58.5M |
Non-operating interest income | -10.81%3.3M | 133.12%35.9M | 167.44%11.5M | 325.00%15.3M | 74.19%5.4M | -15.91%3.7M | 67.39%15.4M | 7.50%4.3M | 50.00%3.6M | 106.67%3.1M |
Non-operating interest expense | 0.00%58.1M | 1.66%238.4M | 4.36%59.9M | 8.81%63M | -6.66%57.5M | 0.87%58.1M | 4.92%234.5M | 2.68%57.4M | 3.76%57.9M | 10.20%61.6M |
Other net income (expense) | 60.98%-11.2M | 48.14%-55.8M | 56.35%-8.6M | 33.82%-9M | 84.30%-9.5M | -107.97%-28.7M | -231.08%-107.6M | -212.70%-19.7M | 35.55%-13.6M | -1,851.61%-60.5M |
Gain on sale of security | 85.61%-2M | -19.90%-24.1M | 45.45%-4.2M | 50.00%-2.9M | ---3.1M | -110.61%-13.9M | -12.29%-20.1M | -60.42%-7.7M | -5.45%-5.8M | ---- |
Other non- operating income (expenses) | 37.84%-9.2M | 63.77%-31.7M | 63.33%-4.4M | 21.79%-6.1M | 89.42%-6.4M | -105.56%-14.8M | -499.32%-87.5M | -700.00%-12M | 50.00%-7.8M | -6,822.22%-60.5M |
Income before tax | 36.72%752.9M | 26.27%3.24B | 22.09%750.6M | 21.55%967.9M | 26.91%972.6M | 41.28%550.7M | 18.19%2.57B | 17.69%614.8M | 19.74%796.3M | 17.35%766.4M |
Income tax | 27.87%134.9M | 25.92%627.6M | 37.78%135.3M | 14.98%181.1M | 21.34%205.8M | 44.13%105.5M | 32.59%498.4M | 33.61%98.2M | 50.43%157.5M | 24.16%169.6M |
Net income | 38.49%609.1M | 26.83%2.59B | 20.55%611.9M | 23.03%777.9M | 28.64%759.9M | 41.37%439.8M | 15.04%2.04B | 14.32%507.6M | 14.46%632.3M | 14.72%590.7M |
Net income continuous Operations | 38.81%618M | 26.36%2.61B | 19.11%615.3M | 23.17%786.8M | 28.49%766.8M | 40.62%445.2M | 15.18%2.07B | 15.08%516.6M | 14.01%638.8M | 15.55%596.8M |
Net income discontinuous operations | -64.81%-8.9M | 9.19%-24.7M | 62.22%-3.4M | -36.92%-8.9M | -13.11%-6.9M | 1.82%-5.4M | -26.51%-27.2M | -83.67%-9M | 17.72%-6.5M | -281.25%-6.1M |
Minority interest income | 20.00%4.2M | 21.35%21.6M | 130.30%7.6M | -1.67%5.9M | 2.22%4.6M | -12.50%3.5M | -2.20%17.8M | -32.65%3.3M | 33.33%6M | -19.64%4.5M |
Net income attributable to the parent company | 38.64%604.9M | 26.88%2.57B | 19.83%604.3M | 23.26%772M | 28.85%755.3M | 42.07%436.3M | 15.22%2.02B | 14.85%504.3M | 14.31%626.3M | 15.10%586.2M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 38.64%604.9M | 26.88%2.57B | 19.83%604.3M | 23.26%772M | 28.85%755.3M | 42.07%436.3M | 15.22%2.02B | 14.85%504.3M | 14.31%626.3M | 15.10%586.2M |
Basic earnings per share | 40.63%2.7 | 28.25%11.35 | 21.27%2.6921 | 24.82%3.42 | 29.57%3.33 | 43.28%1.92 | 17.22%8.85 | 15.68%2.2199 | 16.10%2.74 | 17.89%2.57 |
Diluted earnings per share | 40.53%2.67 | 28.16%11.24 | 21.46%2.66 | 24.63%3.39 | 29.41%3.3 | 42.86%1.9 | 17.25%8.77 | 15.87%2.19 | 16.24%2.72 | 18.06%2.55 |
Dividend per share | 11.90%0.94 | 12.00%3.36 | 12.00%0.84 | 12.00%0.84 | 12.00%0.84 | 12.00%0.84 | 11.94%3 | 11.94%0.75 | 11.94%0.75 | 11.94%0.75 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |